Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT07495813 für Stable Coronary Artery Disease, Gesunde Freiwillige ist offene rekrutierung. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
Zurück zur Suche
RocheA Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease Phase 1 196
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT07495813 untersucht Behandlung im Zusammenhang mit Stable Coronary Artery Disease, Gesunde Freiwillige. Diese interventionsstudie der Phase 1 hat den Status offene rekrutierung und startete am 31. März 2026. Es ist geplant, 196 Teilnehmer aufzunehmen. Durchgeführt von Roche wird der Abschluss für 31. Dezember 2027 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 27. März 2026 aktualisiert.
Kurzbeschreibung
This study will evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses (SAD) (Part 1a), multiple ascending doses (MAD) (Part 1b), and the food effect (Part 1c) of RO7763505 in healthy adult participant. In Part 2, the safety, tolerability, PK and PD of multiple doses of RO7763505 in participants with stable coronary artery diseases (CAD).
Offizieller Titel
A Phase I, Randomized, Double-Blind, Adaptive, Placebo-Controlled, Single- Ascending Dose and Multiple-Ascending Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of RO7763505 Following Oral Administration in Healthy Participants and Patients With Stable Coronary Artery Disease
Erkrankungen
Stable Coronary Artery DiseaseGesunde FreiwilligeWeitere Studien-IDs
- BP46355
- 2025-524693-42-00 (EU CTIS-Studiennummer)
NCT-Nummer
Studienbeginn (tatsächlich)
2026-03-31
Zuletzt aktualisiert
2026-03-27
Studienende (vorauss.)
2027-12-31
Geplante Rekrutierung
196
Studientyp
Interventionsstudie
PHASE
Phase 1
Status
Offene Rekrutierung
Primäres Ziel
Behandlung
Zuteilungsmethode
Randomisiert
Interventionsmodell
Parallel
Verblindung
Dreifach verblindet
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
ExperimentellPart 1: SAD, MAD, and Food Effect in Healthy Participants Healthy participants will receive RO7763505 or matching placebo. | RO7763505 Participants will receive RO7763505 as per the schedule described in the protocol. PLACEBO Participants will receive matching placebo as per the schedule described in the protocol. |
ExperimentellPart 2: In Stable CAD Participants Participants with stable CAD will receive RO7763505 or matching placebo. | RO7763505 Participants will receive RO7763505 as per the schedule described in the protocol. PLACEBO Participants will receive matching placebo as per the schedule described in the protocol. |
Hauptergebnismessungen
Nebenergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Part 1a and Part 1b: Percentage of Participants With Adverse Events (AEs) | Part 1a: Approximately up to 2 Weeks; Part 1b: Approximately up to 3 Weeks | |
Part 1c: Plasma Concentration of RO7763505 in Fasted and fed State | Approximately up to 3 Weeks | |
Part 2: Percentage of Participants With AEs | Approximately up to 6 Weeks |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Part 1a and Part 1b: Plasma Concentration of RO7763505 and its Metabolites | Part 1a: Approximately up to 2 Weeks; Part 1b: Approximately up to 3 Weeks | |
Part 1a and Part 1b: Percentage Change From Baseline in Inhibition of Ex Vivo-Stimulated Interleukin-1 Beta ( IL-1β) | Part 1a: Baseline, Approximately up to 2 Weeks; Part 1b: Baseline, Approximately up to 3 Weeks | |
Part 1c: Percentage of Participants With AEs | Approximately up to 3 Weeks | |
Part 2: Plasma Concentration of RO7763505 and its Metabolites | Approximately up to 6 Weeks | |
Part 2: Percentage Change From Baseline in Inhibition of Ex Vivo-Stimulated IL-1β | Baseline, Approximately up to 6 Weeks |
Teilnahme-Assistent
Eignungskriterien
Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
18 Years
Zugelassene Geschlechter
Alle
Akzeptiert gesunde Freiwillige
Ja
Part 1:
- Healthy biologically male and female participants of nonchildbearing potential or childbearing potential with no clinically relevant findings on physical examination at screening or baseline (assessed either on Day -2 or Day -1), including detailed medical and surgical history, vital signs, 12-lead electrocardiogram (ECG), hematology, blood chemistry, serology, and urinalysis
- No suspicion of cognitive impairment/dementia as judged by the Investigator
Part 2:
- Myocardial infarction before the screening visit
- Objective imaging evidence (coronary computed tomography \[CT\] angiography or invasive angiography) of coronary atherosclerosis Participants who underwent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) are eligible if the procedure was done >6 months prior to screening
- A diagnosis of stable CAD, defined as being on stable guideline-directed medical therapy (GDMT) if tolerated for at least 90 days prior to screening with no planned changes or scheduled interventions during the study
- QTc of <= 450 milliseconds (ms) as determined by a single 12-lead ECG recording. If the initial ECG result of the triplicate is exclusionary, consecutive repeat ECG results must be within the acceptable limits. In participants with a stable bundle branch block where the QRS duration is > 120 ms, the QTcF will be calculated as: QTcF - (QRS - 100 ms)
Part 1:
- Any condition or disease detected during the medical interview/physical examination that would render the participant unsuitable for the study, place the participant at undue risk, or interfere with the ability of the participant to complete the study in the opinion of the Investigator
- Vaccination within 28 days prior to Day 1 (non-live vaccines including influenza vaccination are permitted 14 days prior to Day 1) or planned before the end of the study. Investigators are advised to review the immunization status of participants who are considered for treatment with RO7763505 and follow local/national guidance for adult vaccination against infectious disease as they deem relevant
- Positive result on human immunodeficiency virus (HIV)-1 and HIV-2, hepatitis B virus (HBV) (either hepatitis B surface antigen \[HBsAg\] or hepatitis B core antibody \[HBcAb\]), hepatitis C virus (HCV) antibody test, or tuberculosis (TB)
Part 2:
- Individuals with New York Heart Association (NYHA) Class III or IV heart failure
- Known or suspected immunocompromised state
- Treatment with any investigational therapy within 28 days or within five drug-elimination half-lives (whichever is longer; or longer than either if required by local regulations; if the half-life is unknown, the 90-day period applies) prior to Day 1, calculated from the day of the follow-up from the previous study
RocheZentrale Studienkontakte
Kontakt: Reference Study ID Number: BP46355 https://forpatients.roche.com/, 888-662-6728 (U.S. and Canada), [email protected]
1 Studienstandorte in 1 Ländern
ICON Plc (LPRA) - Netherlands, Groningen, 9728 NZ, Netherlands
Offene Rekrutierung